阿那莫林实际使用效果怎么样

Anamorelin has a significant effect in treating cancer cachexia and can increase body weight, muscle mass and appetite in patients with cancer cachexia.

A double-blind clinical trial (ONO-7643-04) enrolled 174 Japanese patients with unresectable stage III/IV non-small cell lung cancer (NSCLC) and cachexia. Patients were randomized to daily oral administration of anamorelin (100 mg) or placebo for 12 weeks.

Results: The least squares mean changes (plus or minus standard errors) in LBM from baseline over 12 weeks were 1.38±0.18 and -0.17±0.17 kg in the anamorelin and placebo groups, respectively (P<.0001). Both treatment groups showed significant differences in changes from baseline in LBM, weight, and anorexia symptoms at all time points. Anamorelin increased prealbumin at weeks 3 and 9. No changes in HGS or 6MWT were detected between the two groups. Treatment of NSCLC patients for 12 weeks was safe and well tolerated.

Conclusion: Anamorelin can significantly increase LBM and improve anorexia symptoms and nutritional status in Japanese patients with advanced non-small cell lung cancer, but it cannot improve motor function.

Anamorelin is approved in Japan for the treatment of cancer cachexia in non-small cell lung cancer, gastric cancer, pancreatic cancer or colorectal cancer malignancies. It was launched on January 22, 2021. It is a selective, new, orally active ghrelin receptor agonist.

The usual dosage of Anamorelin for adults is 2 capsules (100mg) once a day. Take it on an empty stomach in the morning, and wait 1 hour before eating after taking the medicine.

However, it should be noted that it is prohibited for people with congestive heart failure, myocardial infarction, angina pectoris, atrioventricular block, moderate or above liver dysfunction (Child-Pugh classification B or C), and those with difficulty eating due to digestive abnormalities. In addition, people over 65 years old, young children, pregnant women, and lactating women should use the drug with caution.

Anamorelin improves the patient's weight and appetite, but mildly during medication. Common symptoms include atrioventricular block, tachycardia, bradycardia, palpitations, decreased blood pressure, upper ventricular extrasystoles, hyperglycemia, exacerbation of diabetes, liver dysfunction, etc. Some patients may also experience dry mouth, thirst, vomiting, diarrhea, headache, etc. It is recommended that patients take medication under the guidance of a doctor and receive symptomatic treatment.

Recommended related articles:

References

Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018 Feb 1;124(3):606-616. doi: 10.1002/cncr.31128. Epub 2017 Dec 4. PMID: 29205286; PMCID: PMC5814824.